Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 6/2000

01-05-2000 | ORIGINAL PAPER

Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N 4-alkyl-1-β-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5′→ 5′)-N 4-octadecyl-1-β-d-arabinofuranosylcytosine

Authors: Daniel H. Horber, Rosanna M. C. Cattaneo-Pangrazzi, Prisca von Ballmoos, Herbert Schott, Peter S. Ludwig, Staffan Eriksson, Iduna Fichtner, Reto A. Schwendener

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2000

Login to get access
Metadata
Title
Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N 4-alkyl-1-β-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5′→ 5′)-N 4-octadecyl-1-β-d-arabinofuranosylcytosine
Authors
Daniel H. Horber
Rosanna M. C. Cattaneo-Pangrazzi
Prisca von Ballmoos
Herbert Schott
Peter S. Ludwig
Staffan Eriksson
Iduna Fichtner
Reto A. Schwendener
Publication date
01-05-2000
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 6/2000
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s004320050349

Other articles of this Issue 6/2000

Journal of Cancer Research and Clinical Oncology 6/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine